[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"growth-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:growth-disorders":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,64,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100518971","the-efficacy-and-safety-of-pegylated-gh-for-the-treatment-of-short-stature-in-chinese-children-globe-reg-100518971",false,"NCT06037473","The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg","A Real-world Study of the Efficacy and Safety of PEGylated Recombinant Human Growth Hormone Injection in the Treatment of Short Stature in Chinese Children From the Global Registry for Novel Therapies For Rare Bone or Endocrine Conditions","Inclusion Criteria:\n\nPatients with endogenous growth hormone deficiency, Turner Syndrome, SGA, idiopathic short stature, etc. treated with polyethylene glycol recombinant human growth hormone injection\n\nExclusion Criteria:\n\nPatients with serious heart and lung, blood system, malignant tumors and other diseases or systemic infections, immune function is low and Persons with mental illness;","ALL","18 Years",{"count":19,"type":20},2600,"ESTIMATED","OBSERVATIONAL","In order to further observe the long-term safety and effectiveness of real-world polyethylene glycol-recombinant human growth hormone(PEG-rhGH) treatment of GHD, idiopathic short stature, and SGA in children, explore and analyze the factors affecting the efficacy of PEG-rhGH and the height prediction model after treatment, etc., collect and analyze more scientifically and rationally, and understand the situation of real-world PEG-GH treatment. A database registration study was developed.",[24,25],"Growth Hormone Treatment","Growth Disorders","RECRUITING","2025-08-28",{"date":29,"type":30},"2025-09-04","ACTUAL",{"date":32,"type":30},"2023-08-01",{"date":34,"type":20},"2029-08-01",{"name":36,"class":37},"Beijing Children's Hospital","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":38},"100566966","impact-of-iron-deficiency-anemia-on-neurobehavioral-and-cognitive-development-in-children-aged-6-to-24-months-100566966","NCT06662045","Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 Months","Study on the Association Between Iron Deficiency Anemia and Neurobehavioral Development and Cognitive Function in Children Aged 6 to 24 Months","Inclusion Criteria:\n\n* Children aged 6 to 24 months at the time of enrollment\n* Diagnosed with iron-deficiency anemia (for the exposure group) or confirmed\n* non-anemic status (for the control group) based on blood test results\n* Resident in the study area for at least 6 months prior to enrollment\n* Availability of parental or guardian consent to participate in the study and willingness to follow study protocols\n* Completion of all baseline assessments, including neurodevelopmental and physical growth evaluations\n\nExclusion Criteria:\n\n* Presence of congenital or chronic illnesses that could affect\n* neurodevelopment, such as Down syndrome or cerebral palsy.\n* History of severe infections or trauma within 3 months prior to enrollment that\n* could influence neurodevelopmental outcomes\n* Current use of medications or treatments that may interfere with iron metabolism (e.g., iron supplementation or blood transfusions in the last 6 months)\n* Premature birth (before 37 weeks of gestation) or low birth weight (\\\u003C 2,500 grams)\n* Parental refusal to provide consent or non-compliance with study procedures.","6 Months","6 Years",{"count":49,"type":20},1000,"The goal of this observational study is to explore the relationship between iron-deficiency anemia and neurobehavioral development in children aged 6-24 months. This study focuses on children who undergo health check-ups and blood tests at pediatric health clinics in Pingshan District, Shenzhen, China.\n\nThe main questions it aims to answer are:\n\nHow does iron-deficiency anemia affect children's neurobehavioral development, including motor skills, language ability, and social behavior? How does anemia influence growth and nutrition, such as weight, height, and body mass index (BMI) in children?\n\nParticipants will:\n\nUndergo blood tests (including hemoglobin levels, serum ferritin, and serum iron) to assess anemia status.\n\nBe assessed using the \"Neuropsychological Behavioral Development Scale for Children Aged 0-6\" to measure motor, cognitive, language, and social development.\n\nProvide general health information, such as birth history, feeding methods, and parental details, through interviews with trained surveyors.\n\nResearchers will compare children with and without iron-deficiency anemia to determine differences in neurobehavioral outcomes and development levels. The findings aim to provide evidence for early interventions to prevent the negative impacts of anemia and support children's healthy development.",[52,53,25,54],"Iron-Deficiency Anemia","Neurobehavioral Manifestations","Nutritional Status","2024-10-25",{"date":57,"type":30},"2024-10-28",{"date":59,"type":30},"2024-01-01",{"date":61,"type":20},"2027-06-30",{"name":63,"class":37},"Pingshan District Maternal & Child Healthcare Hospital of Shenzhen",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":38},"100307559","identifying-new-genetic-causes-to-development-disorders-100307559","NCT03283852","Identifying New Genetic Causes to Development Disorders","Identifying New Genetic Causes to the Disorders of Growth, Puberty and Sex Development","FORDEV","Inclusion Criteria:\n\n* congenital growth hormone deficiency\n* puberty disorder\n* gonadal dysgenesis or anorchia\n* primary ovarian failure\n* disorder of sex development\n* subjects related to a patient with one of the above criteria\n\nExclusion Criteria:\n\n* environmental or auto-immune cause",{"count":73,"type":20},1100,"Disorders of growth, puberty and sex development can have genetic causes. The exome analysis could detect new mutations responsible for these disorders and the frequency of these mutations in these disorders, their association with other malformations.",[76,25,77],"Disorders of Sex Development","Puberty Disorders","2024-06-04",{"date":80,"type":30},"2024-06-05",{"date":82,"type":30},"2017-02-21",{"date":84,"type":20},"2027-02-21",{"name":86,"class":87},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":97,"targetDuration":17,"studyType":21,"phases":4,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":38},"100291343","crescnet---growth-monitoring-network-100291343","NCT03072537","CrescNet - Growth Monitoring Network","CrescNet - Computer-guided, Population-based Surveillance System for Growth Disorders","CrescNet","Inclusion Criteria: Population based sample with inclusion of any patient seen by primary care or institutional physician\u002Fpediatrician, regardless of the objective for the visit (well child visits, acute visits or special requests)\n\nExclusion Criteria: none",true,{"count":98,"type":20},1000000,"CrescNet is a network of primary care physicians and pediatricians (n=219) and endocrinological treatment centers (n=33), established in Leipzig in 1998, whose aim is to improve the early detection of growth disorders. Secondary to this clinical aim, epidemiological analyses, for example on secular trends of growth data of children, are performed.",[101,102,25],"Obesity","Child Development",[104,105,106,107,108,109],"growth","BMI","obesity","childhood","adolescence","development","2023-11-03",{"date":112,"type":30},"2023-11-07",{"date":114,"type":30},"1998-01-01",{"date":116,"type":20},"2028-01-01",{"name":118,"class":37},"University of Leipzig"]